Xiaohui Ma

TL;DR: Theabrownin alters the gut microbiota in mice and humans, predominantly suppressing microbes associated with bile-salt hydrolase (BSH) activity, and it is suggested that decreased intestinal BSH microbes and/or decreased FXR-FGF15 signaling may be potential anti- hypercholesterolemia and anti-hyperlipidemia therapies.

TL;DR: In this paper, the authors investigate whether human HCA profiles can predict the development of metabolic disorders and find that both obesity and diabetes are associated with lower serum concentrations of HCA species.

TL;DR: It is demonstrated that theabrownin ameliorated high-fat-diet (HFD)-induced obesity by modifying gut microbiota, especially those with 7α-dehydroxylation on the species level, and these changed microbes were positively correlated with secondary bile acid (BA) metabolism.

TL;DR: An R package, polyPK, is introduced, the first and only automation of the data analysis pipeline of Poly‐PK strategy, to simultaneously monitor the performance of drug constituents and endogenous metabolites, taking into account both the diversity of the drug's chemical composition and its complex effects on the mammalian metabolic pathways.